Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cholera vaccine inactivated oral - Valneva

Drug Profile

Cholera vaccine inactivated oral - Valneva

Alternative Names: Vibrio cholerae and enterotoxigenic Escherichia coli vaccine - Crucell/sanofi-aventis; Dukoral; SBL Cholera Vaccine; WC/rBS; whole cell/recombinant B subunit cholera vaccine

Latest Information Update: 14 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SBL Vaccin AB
  • Developer Crucell; Valneva
  • Class Cholera vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cholera; Escherichia coli infections

Most Recent Events

  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 26 Jan 2016 IC 51 sub-licensed to GlaxoSmithKline in Germany
  • 23 Jul 2015 Inactivated oral cholera vaccine (Dukoral®) licensed to PaxVax for commercialisation in Italy, Spain and Portugal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top